JP7083214B2 - 膵がんを治療する方法 - Google Patents

膵がんを治療する方法 Download PDF

Info

Publication number
JP7083214B2
JP7083214B2 JP2018565305A JP2018565305A JP7083214B2 JP 7083214 B2 JP7083214 B2 JP 7083214B2 JP 2018565305 A JP2018565305 A JP 2018565305A JP 2018565305 A JP2018565305 A JP 2018565305A JP 7083214 B2 JP7083214 B2 JP 7083214B2
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
modulator
halogen
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018565305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518038A5 (zh
JP2019518038A (ja
Inventor
ベッカー，ペトルス
ミヤオ，シーチャーン
チャロ，イスラエル
シャル，トム
Original Assignee
ケモセントリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス， インコーポレイテッド filed Critical ケモセントリックス， インコーポレイテッド
Publication of JP2019518038A publication Critical patent/JP2019518038A/ja
Publication of JP2019518038A5 publication Critical patent/JP2019518038A5/ja
Application granted granted Critical
Publication of JP7083214B2 publication Critical patent/JP7083214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018565305A 2016-06-13 2017-06-13 膵がんを治療する方法 Active JP7083214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662349217P 2016-06-13 2016-06-13
US62/349,217 2016-06-13
US201662382689P 2016-09-01 2016-09-01
US62/382,689 2016-09-01
PCT/US2017/037264 WO2017218544A1 (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020103107A Division JP2020147602A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法
JP2020103105A Division JP2020147601A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法

Publications (3)

Publication Number Publication Date
JP2019518038A JP2019518038A (ja) 2019-06-27
JP2019518038A5 JP2019518038A5 (zh) 2020-07-27
JP7083214B2 true JP7083214B2 (ja) 2022-06-10

Family

ID=60663739

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018565305A Active JP7083214B2 (ja) 2016-06-13 2017-06-13 膵がんを治療する方法
JP2020103105A Withdrawn JP2020147601A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法
JP2020103107A Withdrawn JP2020147602A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020103105A Withdrawn JP2020147601A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法
JP2020103107A Withdrawn JP2020147602A (ja) 2016-06-13 2020-06-15 膵がんを治療する方法

Country Status (14)

Country Link
EP (1) EP3468548B1 (zh)
JP (3) JP7083214B2 (zh)
KR (2) KR20190017913A (zh)
CN (1) CN109562086A (zh)
AU (1) AU2017283491B2 (zh)
BR (1) BR112018075660A2 (zh)
CA (1) CA3026515A1 (zh)
ES (1) ES2895749T3 (zh)
IL (1) IL263508B2 (zh)
MX (1) MX2018015172A (zh)
RU (1) RU2768479C2 (zh)
SG (2) SG11201810940XA (zh)
WO (1) WO2017218544A1 (zh)
ZA (1) ZA201808258B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
BR112018075660A2 (pt) * 2016-06-13 2019-04-09 Chemocentryx, Inc. métodos de tratamento de câncer de pâncreas
CN112714648B (zh) * 2018-09-19 2024-05-14 奥托泰利克生物公司 抗癌用组合物
WO2022042537A1 (zh) * 2020-08-24 2022-03-03 江苏恒瑞医药股份有限公司 TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用
CN116804221B (zh) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Lmo7表达水平在预测胰腺癌吉西他滨耐药中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533203A (ja) 2007-07-12 2010-10-21 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
US20140031348A1 (en) 2006-07-14 2014-01-30 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2/ccr9
JP2020147601A (ja) 2016-06-13 2020-09-17 ケモセントリックス， インコーポレイテッド 膵がんを治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52010B (en) * 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
CA2669917A1 (en) * 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
BRPI0907236A2 (pt) * 2008-01-22 2017-06-06 Merck Patent Ges Mit Berschränkter Haftung inibidores de proteína quinase e uso dos mesmos
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102933579B (zh) * 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 新的ccr2受体拮抗剂及其用途
DK3263564T3 (da) * 2012-02-29 2020-09-07 Chemocentryx Inc Aza-aryl-1h-pyrazol-1-yl-benzen-sulfonamider som ccr(9)- antagonister
JP6523337B2 (ja) * 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031348A1 (en) 2006-07-14 2014-01-30 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2/ccr9
JP2010533203A (ja) 2007-07-12 2010-10-21 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
JP2020147601A (ja) 2016-06-13 2020-09-17 ケモセントリックス， インコーポレイテッド 膵がんを治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet Oncol.，2016年04月04日，Vol.17，pp.651-662

Also Published As

Publication number Publication date
RU2019100220A3 (zh) 2020-12-24
CA3026515A1 (en) 2017-12-21
IL263508B2 (en) 2023-06-01
AU2017283491A1 (en) 2018-12-20
EP3468548A1 (en) 2019-04-17
KR20230047210A (ko) 2023-04-06
IL263508A (en) 2019-01-31
CN109562086A (zh) 2019-04-02
SG10202012434QA (en) 2021-01-28
SG11201810940XA (en) 2019-01-30
JP2020147602A (ja) 2020-09-17
ES2895749T3 (es) 2022-02-22
JP2020147601A (ja) 2020-09-17
RU2768479C2 (ru) 2022-03-24
RU2019100220A (ru) 2020-07-15
KR20190017913A (ko) 2019-02-20
AU2017283491B2 (en) 2021-06-03
EP3468548B1 (en) 2021-08-04
ZA201808258B (en) 2022-04-28
WO2017218544A1 (en) 2017-12-21
EP3468548A4 (en) 2020-01-22
JP2019518038A (ja) 2019-06-27
BR112018075660A2 (pt) 2019-04-09
MX2018015172A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
JP7083214B2 (ja) 膵がんを治療する方法
US11890276B2 (en) Methods of treating pancreatic cancer
US10251888B2 (en) Method of treating pancreatic cancer
AU2016357413B2 (en) Modulators of chemokine receptors
KR101184036B1 (ko) Ｐａｒｐ 저해제로서의 치환 ２-알킬 퀴나졸리논 유도체
JP6804516B2 (ja) 変異イソクエン酸デヒドロゲナーゼｉｄｈ１ ｒ１３２ｈの阻害剤
CN109311843A (zh) 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物
CN105555786A (zh) 作为BET蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮
JP2003532713A (ja) Ｈｉｖ複製阻害性ピリミジンのプロドラッグ
EA019064B1 (ru) Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
EA018964B1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
CN115666561A (zh) Cns的增殖性疾病的治疗
ES2295897T3 (es) Efectos inmunodepresores de derivados de pteridina.
WO2017202311A1 (zh) 一种2-氨基嘧啶类化合物的多晶型形式
WO2018050108A1 (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
KR20240110902A (ko) 췌장 암을 치료하는 방법
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
WO2024073328A2 (en) Methods of treating cancer and compositions for the same
BR112018009880B1 (pt) Compostos e composições farmacêuticas moduladores dos receptores de quimiocina e seus usos
WO2014154026A1 (zh) PI3K和/或mTOR抑制剂的前药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200615

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200618

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20210104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220527

R150 Certificate of patent or registration of utility model

Ref document number: 7083214

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150